Literature DB >> 14517490

The role of soluble cell adhesion molecules in patients with suspected deep vein thrombosis.

Robert A Bucek1, Markus Reiter, Peter Quehenberger, Erich Minar, Mehrdad Baghestanian.   

Abstract

Activation of the endothelium, platelets and leukocytes has been shown to play an important role in the aetiology of deep venous thrombosis (DVT) in in-vitro experiments, resulting in the release of soluble cell adhesion molecules (sCAMs). We therefore assessed the value of soluble intracellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin and soluble P-selectin for the diagnostic process in 69 consecutive patients with suspected DVT. Final diagnosis was based on the results of Duplex sonography or ascending venography. Thirty-seven patients (53.6%) finally suffered from DVT. Mean levels of sVCAM-1 were 589 +/- 530 ng/ml for controls and 587 +/- 328 ng/ml for patients. Corresponding levels concerning sICAM-1 were 316 +/- 161 and 342 +/- 186 ng/ml, those concerning soluble E-selectin were 54 +/- 38 and 42 +/- 18 ng/ml, and those concerning soluble P-selectin were 94 +/- 37 and 99 +/- 36 ng/ml (all P > 0.05). There was no significant correlation of the thrombus extension (all P > 0.05) or the duration of symptoms with sCAMs (all P > 0.05). In conclusion, we detected no significant differences concerning the concentration of four major sCAMs between patients with DVT and controls, so their assessment does not add any useful information for the diagnostic process of DVT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517490     DOI: 10.1097/00001721-200310000-00006

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  7 in total

Review 1.  Venous Thrombosis and Post-Thrombotic Syndrome: From Novel Biomarkers to Biology.

Authors:  Allan K Metz; Jose A Diaz; Andrea T Obi; Thomas W Wakefield; Daniel D Myers; Peter K Henke
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Jul-Sep

2.  Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis.

Authors:  Eduardo Ramacciotti; Susan Blackburn; Angela E Hawley; Frank Vandy; Nicole Ballard-Lipka; Cathy Stabler; Nichole Baker; Kenneth E Guire; John E Rectenwald; Peter K Henke; Daniel D Myers; Thomas W Wakefield
Journal:  Clin Appl Thromb Hemost       Date:  2011-05-17       Impact factor: 2.389

3.  Search for Venous Endothelial Biomarkers Heralding Venous Thromboembolism in Space: A Qualitative Systematic Review of Terrestrial Studies.

Authors:  Katie Harris; Jonathan Michael Laws; Antoine Elias; David Andrew Green; Nandu Goswami; Jens Jordan; Tovy Haber Kamine; Lucia Mazzolai; Lonnie G Petersen; Andrew James Winnard; Tobias Weber
Journal:  Front Physiol       Date:  2022-04-27       Impact factor: 4.755

4.  Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis.

Authors:  Knut Anders Mosevoll; Roald Lindås; Oystein Wendelbo; Oystein Bruserud; Håkon Reikvam
Journal:  Springerplus       Date:  2014-09-30

Review 5.  Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis.

Authors:  Knut A Mosevoll; Silje Johansen; Øystein Wendelbo; Ina Nepstad; Øystein Bruserud; Håkon Reikvam
Journal:  Front Med (Lausanne)       Date:  2018-05-22

Review 6.  P- and E- selectin in venous thrombosis and non-venous pathologies.

Authors:  Megan Purdy; Andrea Obi; Daniel Myers; Thomas Wakefield
Journal:  J Thromb Haemost       Date:  2022-03-25       Impact factor: 16.036

7.  Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome.

Authors:  Luis Fernando Bittar; Letícia Queiroz da Silva; Fernanda Loureiro de Andrade Orsi; Kiara Cristina Senger Zapponi; Bruna de Moraes Mazetto; Erich Vinícius de Paula; Silmara Aparecida de Lima Montalvão; Joyce Maria Annichino-Bizzacchi
Journal:  PLoS One       Date:  2020-01-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.